Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib.

Koizumi T, Agatsuma T, Ikegami K, Suzuki T, Kobayashi T, Kanda S, Yoshikawa S, Kubo K, Shiina T, Takasuna K, Matsuo A, Hayasaka M, Morikawa M, Ameshima S.

Clin Lung Cancer. 2012 Nov;13(6):458-63. doi: 10.1016/j.cllc.2012.01.006. Epub 2012 Mar 7.

PMID:
22402083
2.

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.

Yokouchi H, Yamazaki K, Kinoshita I, Konishi J, Asahina H, Sukoh N, Harada M, Akie K, Ogura S, Ishida T, Munakata M, Dosaka-Akita H, Isobe H, Nishimura M.

BMC Cancer. 2007 Mar 20;7:51.

3.

Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib.

Asahina H, Oizumi S, Inoue A, Kinoshita I, Ishida T, Fujita Y, Sukoh N, Harada M, Maemondo M, Saijo Y, Dosaka-Akita H, Isobe H, Nukiwa T, Nishimura M; Hokkaido Lung Cancer Clinical Study Group.

Oncology. 2010;79(5-6):423-9. doi: 10.1159/000326488. Epub 2011 Apr 8.

PMID:
21474967
5.

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.

Watanabe S, Tanaka J, Ota T, Kondo R, Tanaka H, Kagamu H, Ichikawa K, Koshio J, Baba J, Miyabayashi T, Narita I, Yoshizawa H.

BMC Cancer. 2011 Jan 1;11:1. doi: 10.1186/1471-2407-11-1.

6.

Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study.

Oh IJ, Ban HJ, Kim KS, Kim YC.

Lung Cancer. 2012 Jul;77(1):121-7. doi: 10.1016/j.lungcan.2012.01.012. Epub 2012 Feb 12.

PMID:
22333554
7.

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer.

Yin YM, Geng YT, Shao YF, Hu XL, Li W, Shu YQ, Wang ZX.

J Exp Clin Cancer Res. 2010 Sep 15;29:126. doi: 10.1186/1756-9966-29-126.

8.

[Gefitinib in the treatment of advanced non-small cell lung cancer].

Yang L, Liu XY, Fang J, An TT, Wu MN.

Zhonghua Zhong Liu Za Zhi. 2006 Jun;28(6):474-7. Chinese.

PMID:
17152500
9.

[Clinical response to gefitinib retreatment of lung adenocarcinoma patients who benefited from an initial gefitinib therapy: a retrospective analysis].

Li J, Hao X, Wang Y, Zhang X, Shi Y.

Zhongguo Fei Ai Za Zhi. 2012 Jan;15(1):44-8. doi: 10.3779/j.issn.1009-3419.2012.01.09. Chinese.

10.

A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment.

Nishino K, Imamura F, Morita S, Mori M, Komuta K, Kijima T, Namba Y, Kumagai T, Yamamoto S, Tachibana I, Nakazawa Y, Uchida J, Minami S, Takahashi R, Yano Y, Okuyama T, Kumanogoh A.

Lung Cancer. 2013 Nov;82(2):299-304. doi: 10.1016/j.lungcan.2013.08.009. Epub 2013 Aug 21.

PMID:
24018023
11.

[Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].

Fan Y, Huang ZY, Yu HF, Luo LH.

Zhonghua Zhong Liu Za Zhi. 2010 Nov;32(11):859-63. Chinese.

PMID:
21223694
12.

Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.

Sunaga N, Tomizawa Y, Yanagitani N, Iijima H, Kaira K, Shimizu K, Tanaka S, Suga T, Hisada T, Ishizuka T, Saito R, Dobashi K, Mori M.

Lung Cancer. 2007 Jun;56(3):383-9. Epub 2007 Mar 26.

PMID:
17368623
13.

[Efficacy of erlotinib after the failure of gefitinib in patients with metastasis of non-small cell lung cancer with unknown EGFR mutation status].

Wang Y, Li JL, Wang ZP, Hao XZ, Wang B, Zhang XR, Shi YK.

Zhonghua Zhong Liu Za Zhi. 2012 Oct;34(10):780-4. doi: 10.3760/cma.j.issn.0253-3766.2012.10.013. Chinese.

PMID:
23291074
14.
15.

Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.

Asami K, Koizumi T, Hirai K, Ameshima S, Tsukadaira A, Morozumi N, Morikawa A, Atagi S, Kawahara M.

Clin Lung Cancer. 2011 Nov;12(6):387-92. doi: 10.1016/j.cllc.2011.02.004. Epub 2011 May 10.

PMID:
21729650
16.

Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.

Cho BC, Im CK, Park MS, Kim SK, Chang J, Park JP, Choi HJ, Kim YJ, Shin SJ, Sohn JH, Kim H, Kim JH.

J Clin Oncol. 2007 Jun 20;25(18):2528-33.

PMID:
17577030
17.

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J.

J Clin Oncol. 2003 Jun 15;21(12):2237-46. Epub 2003 May 14. Erratum in: J Clin Oncol. 2004 Dec 1;22(23):4863.

PMID:
12748244
18.

Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer.

Reck M, Buchholz E, Romer KS, Krutzfeldt K, Gatzemeier U, Manegold C.

Clin Lung Cancer. 2006 May;7(6):406-11.

PMID:
16800967
19.

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group.

N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530.

20.

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.

J Clin Oncol. 2008 May 20;26(15):2442-9. doi: 10.1200/JCO.2007.14.8494. Epub 2008 May 5. Erratum in: J Clin Oncol. 2008 Jul 10;26(20):3472.

PMID:
18458038

Supplemental Content

Support Center